Analytical Data
-
Gene name
RGM-C
- Application
-
Alternative Names
HFE2; HFE2A; HJV; JH; RGMC; hemochromatosis type 2(Juvenile); Haemojuvelin; RGM domain family member C
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q6ZVN8
-
Expression Region
Leu29~Ala401
-
Molecular Weight
43kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
RGM-C (Repulsive Guidance Molecule-C) is a member of the RGM family of proteins and plays a crucial role in various biological processes, including neural development and iron metabolism. Initially identified for its functions in the nervous system, RGM-C has emerged as a key player in regulating nerve growth, axon guidance, and synaptic plasticity. Additionally, it has been implicated in the modulation of the immune response and has shown potential influence on disease pathologies such as neurodegenerative disorders, cancer, and iron-related disorders due to its interaction with the growth factor BMP (Bone Morphogenetic Protein). The study of RGM-C has gained momentum as researchers aim to elucidate its mechanisms of action, the pathways it influences, and its potential as a therapeutic target. Recent advances in recombinant protein technology have enabled the production of RGM-C in a laboratory setting, facilitating in-depth biochemical and functional analyses. This research aims to uncover the physiological roles of RGM-C in health and disease, paving the way for innovative strategies in regenerative medicine and targeted therapies. Understanding RGM-C’s structure-function relationships and its interactions with other molecular partners holds promise for developing novel interventions in neurological and metabolic disorders, making it a significant focus within the realm of protein research and therapeutic development.
